斯坦丁和PCSK9抑制对代谢功能障碍相关的脂肪性肝病的影响
Eleni Theocharidou1, Thomas Gossios2
12nd Aristotle University of Thessaloniki Department of Internal Medicine, Hippokratio General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Journal of digestive diseases
|October 9, 2025
概括
类他类药物在与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者治疗脱脂症方面是有效的,改善了心血管风险和肝脏结果. PCSK9抑制剂显示出有希望的结果,但需要更多的安全数据来治疗MASLD.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脱脂症在与代谢功能障碍相关的脂肪性肝病 (MASLD) 中很普遍,增加了心血管风险.
- 有效的失脂症管理也可能有利于MASLD的进展和结果.
研究的目的:
- 审查目前用于MASLD的低脂性治疗方法的疗效和安全性.
- 评估他类药物和新兴PCSK9抑制剂在MASLD管理中的作用.
主要方法:
- 对MASLD患者的低脂药物发表数据的系统审查.
- 对他类药物和PCSK9抑制剂的临床试验数据和临床前研究的分析.
主要成果:
- 类药物是MASLD中超脂血症的首要治疗方法,在补偿性肝硬化中是安全的,可能降低失补偿和HCC风险.
- 由于不良事件的风险,在不补偿性肝硬化中应谨慎使用他类药物.
- PCSK9抑制剂在MASLD中显示了初步的益处,但临床前数据表明存在潜在的安全问题,例如肝细胞脂质积累.
结论:
- 基于心血管风险分层,建议在MASLD中治疗高脂血症时使用他类药物.
- 需要进一步的研究来确定PCSK9抑制剂在MASLD患者中的安全性和有效性.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
212
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
212
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
212
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
212
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K


